The worldwide tomo mammography market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2025 to 2034. This growth is driven by emerging trends and strong demand across key sectors.
The BCRF supports more than 260 scientists at the leading medical and academic institutions across 16 countries to enhance breast cancer screening and early detection. For instance, in September 2024, the Breast Cancer Research Foundation (BCRF) announced a significant investment of $70.3 million in research projects and scientific grants to over 260 researchers for the treatment, prevention, and end of breast cancer.
AstraZeneca aims to transform breast cancer care for underserved patient populations. For instance, in April 2024, AstraZeneca funded the initiative named ‘The Powering Breast Cancer Progress (PBCP) grant program which is supported by ‘Charities Aid Foundation’ (CAF) to improve health outcomes for underserved patient populations.
The R&D process for tomosynthesis or tomo mammography involves hardware innovation, advanced software and AI integration, and expanded clinical applications. The R&D process phases include fundamental research, concept validation, prototype development, pre-clinical testing, clinical evaluation, clinical trials, market launch, and post-market surveillance.
Key Players: Hologic, Inc., GE Healthcare, Siemens Healthineers, Fujifilm Holdings Corporation, iCAD, Inc.
The distribution to hospitals is managed through different channels like direct-to-hospital sales, specialized medical equipment distributors, government-led initiatives, and specialty clinics. The in-vitro diagnostic devices, single-use surgical items, home healthcare products, etc., are associated with distribution to pharmacies.
Key Players: GE Healthcare, Hologic, Inc., Fujifilm Corporation, Siemens Healthineers, Canon Medical Systems, etc.
These services and solutions include integrated care, clinical services, management of patient comfort, anxiety, financial assistance, insurance navigation, patient education, and advocacy.
Key Players: Hologic, Inc., GE Healthcare, Siemens Healthineers, Fujifilm Holdings Corporation.
In November 2024, Toshio Takiguchi, President and CEO of Canon Medical Systems, announced a global initiative named ‘Screen for Life, Breathe with Hope’, which is designed to advance lung cancer screening efforts, promote early detection, and reduce lung cancer-related mortality.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
